Comparison of the effects of sugamadex dosage on the reversal of neuromuscular blockadeand recovery profile in adult patients under general anesthesia

Comparison of the effects of sugammadex recommended dose (2mg/kg) and fixed dose of 200mg on the reversal of moderate neuromuscular block and recovery profile in adult patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008773

Enrollment

Registered

2023-09-07

Start date

2023-11-23

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In both groups, the depth of neuromuscular block at the end of surgery was aimed at moderate neuromuscular block. After the operation is completed, the dose of sugammadex, a reversal agent for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for surgery under general anesthesia 2. American Society of Anesthesiologist Patient Status I~II (I is a normal healthy patient, II is patient with mild systemic disease). 3. 19~ 65 year old 4. Body weight equal to or less than 90kg

Exclusion criteria

Exclusion criteria: - Contraindications to the use of sugammadex - Body mass index >30 kg/m2 - Neuromuscular disease - Moderate or severe liver, kidney, heart, or respiratory disease - Cognitive impairment

Design outcomes

Primary

Measure	Time frame
speed of reversal of neuromuscular block (i.e. time to reach train-of-four [TOF] ratio 0.9)	—

Secondary

Measure	Time frame
Time required for endotracheal tube extubation after administration of sugammadex	—

Countries

Korea, Republic of

Contacts

Public ContactTae-Yun Sung

Konyang University Hospital

unt1231@naver.com+82-42-600-9316

Outcome results